dermatological · treatments for mild-to-moderate atopic dermatitis (ad) moa: pde4 inhibitor...
TRANSCRIPT
![Page 1: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/1.jpg)
![Page 2: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/2.jpg)
DERMATOLOGICAL DRUGS UPDATE 2016
DR. CHARLES W. LYNDE, MD, FRCPCDiplomate American Boards Dermatology
Associate Professor, Department of Medicine, University of Toronto
WWW.DERMATOLOGYUPDATE.COM
![Page 3: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/3.jpg)
OBJECTIVES
1. To be familiar with the key dermatological therapeutics of 2016
2. To translate this information into changing clinical practice
![Page 4: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/4.jpg)
DISCLOSURES •3M•EMD Serono•Ontario Government (DQTC)•Abbott•Galderma•Ortho Biotech•Allergan•Graceway•Pfizer•Amgen•Glaxo Smith Kline•Westwood Squibb
•Pierre Febrre•Astellas•Global Trox•PremPharm•Avene•H3 Pharmaceuticals•Procyon•Barrier•Hval•Roche•Dravis
•Basilea•Isotechnika•Sanofi Aventis•Berlex•Innovaderm•Schering Plough•Biogen Idec•Janssen•Stiefel•Boehringer Ingelheim•NanoBio
•Lederle•TEVA•Celgene•Leo Pharma•Tribute•Centocor•L’Oreal•Valeant•Cipher•Merck Frosst•Wyeth•Eli Lilly•Novartis
Dr. Charles W. Lynde, MD, FRCPC
![Page 5: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/5.jpg)
DISCLAIMER
Please note that this presentation does contain some discussion of “off-label” uses for
pharmaceutical products
![Page 6: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/6.jpg)
BOLDLY GOING WHERE NO DERMATOLOGIST HAS GONE BEFORE.
![Page 7: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/7.jpg)
![Page 8: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/8.jpg)
A PARADIGM SHIFT IN AD
Bieber, T. Atopic Dermatitis: New Frontiers, unmet therapeutic needs and treatment advances. WCD. 2015
![Page 9: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/9.jpg)
• Anti-PDE4 (crisaborole, apremilast)
• Anti-IL-17s
• Anti IL12/23 (ustekinumab)
• Anti-TNFs
• Anti-TSLP* (AMG 157)
NEW TARGETS IN AD
Presented at EADV 2016; Session D1T11.1.
• IL-4/13 blockers (dupilumab)
• Anti-IL-5 (mepolizumab)
• Anti-IL-6 (tocilizumab)
• Anti-IgE (omalizumab, ligelizumab)
• Anti-IL-22
• Anti-IL-31
![Page 10: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/10.jpg)
AD LANDSCAPE:2Q 2016 INTELLIGENCE UPDATE
Approval Timeline Pipeline Compounds of Interest
2017 2018 2019 2020 2021 2022 2023
*Filing dates are rough estimates based on best-case scenarios and progress to date. ** Note that dates are estimates for the US market.1May have failed PII; incomplete data released
SC /
IVO
ral
Top
ical
MOA / Class
Crisaborole(Anacor)
Lebrikizumab(Roche)
Tralokinumab(AZ/LEO)
Nemolizumab (Chugai/Galderma)
Ustekinumab(Janssen) Japan only – pilot at Rockefeller
Dupilumab(Regeneron)
Fevipiprant (QAW039)1
(Novartis)
DS107G(dignity Sciences)
Baricitinib(Lilly)
VTP-38543(Vitae/Allergan)
ZPL-389(Ziarco)
Tezepelumab(AZ/Amgen)
GBR30(Glenmark Pharmaceuticals)
IL-4,13
JAK
PDE4
CRTh2 receptor antagonist RTH2
Histamine H4 receptor antagonist
LXRβ agonist
IL-13
IL-31
IL-12/23
Linoleic acid
TSLP
OX40 antagonist
OP-15406(Medimetriks)
![Page 11: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/11.jpg)
AD LANDSCAPEDrug MOA Phase
Route of Administration
ExpectedUS Launch
Dupilumab IL-4, IL-13 III SC 2017
Crisaborole PDE4 Inhibitor III Topical 2017
VTP-38543 LXRβ agonist I / II Topical 2019
Nemolizumab IL-31 II SC 2H 2019/2020
Tralokinumab IL-13 IIb SC 2020
Fevipiprant(QAW039)
CRTh2 Receptor Antagonist
II Oral 2020
Ustekinumab IL-12/23 II (Japan) SC 2020
Baricitinib JAK II Oral QD 2H 2020 / 1H 2021
OPA-15406 PDE4 Inhibitor II Topical 2020+
Tezepelumab TSLP IIa SC 2020+
ZPL-389Histamine H4
Receptor AntagonistIIa Oral 2020+
Lebrikizumab IL-13 II SC 2021
GBR30 OX40 antagonist IIa IV 2021
DS107G Linoleic acid IIb Oral 2021
![Page 12: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/12.jpg)
DUPILUMAB (REGENERON/SANOFI/GENZYME)
Simpson EL, et al. New Engl J Med. 2016; Epub: dol: 10.1056/NEJMoa1610020.
Indicated for: moderate-to-severe ADMoA: IL-4, IL-13 inhibitorOther indication being investigated: Asthma (Phase III), Eosinophilic (Phase II) Launched: late 2016 (US) Canada launch: expected ~ late 2017
![Page 13: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/13.jpg)
LEBRIKIZUMAB (ROCHE)
Indicated for: moderate-to-severe ADMoA: IL-13 inhibitorsOther indication being investigated: IPF, COPD, Hodgkin’sLymphoma, AsthmaLaunched: 2021 (US)
![Page 14: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/14.jpg)
TEZEPELUMAB (MEDIMMUNE/AMGEN)
Indicated for: moderate-to-severe AD Status: Phase II MoA: human monoclonal antibody, inhibits TSLP (ThymicStromal Lymphoprotein)Other indication being investigated: AsthmaLaunched: 2020? (US)
![Page 15: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/15.jpg)
NEMOLIZUMAB (CHUGAI/GALDERMA)
Indicated for: moderate-to-severe AD Status: Phase II MoA: IL-31 inhibitorOther indication being investigated: AsthmaLaunched: late 2019 (US)
![Page 16: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/16.jpg)
DS107G: RATIONALE
• DGLA (Dihomo-gamma-linoleic acid) & its metabolites
• Have been shown to have anti-inflammatory effects
• Purification technologies have advanced enough to allow the purification of GLA from plant oils, and then the conversion of GLA DGLA by the addition of 2 carbons
Tanaka, Takao, Saki Kakutani, Chika Horikawa, Hiroshi Kawashima, and Yoshinobu Kiso. "Oral Supplementation with Dihomo-γ-Linolenic Acid (DGLA)-Enriched Oil Increases Serum DGLA Content in Healthy Adults." Lipids 47.6 (2012): 643-46. Web.
![Page 17: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/17.jpg)
TRALOKINUMAB
Partnership with AstraZeneca, LEO
Pharma acquires the global licence to
tralokinumab in skin diseases
an anti-IL-13 monoclonal antibody that delivered statistically significant
improvements in Eczema Area and Severity Index
(EASI) scores in patients with moderate-to-severe atopic
dermatitis in a 12-week Phase IIb trial.
By Expanding Our Portfolio to Include Both Biologics and Topicals, LEO Pharma Is Set to Become the World Dermatology Leader – Offering the Most Diverse Range of Treatment Solutions to Meet the Individual Needs of People with Skin Diseases,” Sa. "LEO Pharma Enters Biologics through Strategic Partnership with AstraZeneca." LEO Pharma -. N.p., n.d. Web. 02 Nov. 2016.
![Page 18: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/18.jpg)
TOPICALS FOR ATOPIC DERMATITIS
![Page 19: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/19.jpg)
CISBOROLE (ANACOR)AN2898 AND AN2728 TOPICAL
PURPOSE: The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD)MoA: PDE4 inhibitorIdentifier: NCT01301508
"Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis." Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis. N.p., n.d. Web. 19 Nov. 2015.
![Page 20: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/20.jpg)
GSK2894512 (GSK)
• A Randomized, Blinded, Vehicle-Controlled,Dose-Finding Study of GSK2894512 Cream for theTreatment of Atopic Dermatitis
• Status: Recruiting
MoA:
GSK2894512 inhibits the secretion of
multiple pro-inflammatory cytokines and chemokines
At present MoA is not completely understand
"A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)." Home. N.p., n.d. Web. 02 Nov. 2016.
![Page 21: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/21.jpg)
EXCIPIAL (GALDERMA)NEW LINE OF TOPICAL EMOLLIENTS & SKIN PROTECTANTS
• U4: 4% Urea Lotion
• U10: 10% Urea Lotion
• Repair: Enriched with 29.5% lipid content, Provitamin B5 and vitamin B3 and vitamin E together with emollients and skin conditioners to penetrate the skin deeply, relieving dry skin and protecting against external irritants.
• Protect: barrier cream, unscented, 5% aluminium chlorohydrate, parraffinum liquidum
• Bath & Skin Therapy Oil: light scent, vitamin E, almond oil, parraffinum liquidum
"A New Solution for Your Toughest Dry Skin Problems." Excipial -. N.p., n.d. Web. 02 Nov. 2016.
![Page 22: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/22.jpg)
AD PATIENTS ARE ASKING FOR MORE NATURAL PRODUCTS…
In a survey of 1000 US Women in 2015 “The Green Beauty Barameter”
Urbanowicz, Nicole. "Survey: 54% of Women Want Skin Care to Be 'All Natural'" Skin Inc. N.p., n.d. Web. 02 Nov. 2016.
![Page 23: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/23.jpg)
ALL NATURAL PRODUCTS BY SKINFIX
• SkinFix Body Repair Balm:
• Product for atopic dermatitis free of: acids, alcohols, cooling ingredients, essential oils, fragrance, parabens, phthalates, sulfates, scrubs
• Eczema Regime for children:
• Product for atopic dermatitis free of: acids, alcohols, cooling ingredients, essential oils, fragrance, parabens, phthalates, sulfates, scrubs
SkinFixInc. "FAQs - Skinfix Inc." Skinfix Inc. Web. 02 Nov. 2016.
![Page 24: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/24.jpg)
PSORIASIS VULGARIS
![Page 25: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/25.jpg)
Lynde, Charles W., Yves Poulin, Ronald Vender, Marc Bourcier, and Sam Khalil. "Interleukin 17A: Toward a New Understanding of Psoriasis Pathogenesis." Journal of the American Academy of Dermatology 71.1 (2014): 141-50. Web.
PSORIASIS PATHOGENESIS
![Page 26: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/26.jpg)
PSORIASIS GUIDELINES
![Page 27: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/27.jpg)
IL-17 INHIBITORS
• Secukinumab
• Ixekizumab
• Brodalumab
Schmidt, Charlie. "Suicidal Thoughts End Amgen's Blockbuster Aspirations for Psoriasis Drug." Nat Biotechnol Nature Biotechnology 33.9 (2015): 894-95. Web.
![Page 28: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/28.jpg)
SECUKINUMAB
• Indicated for moderate to severe adult PsO (other: uveitis, rheumatoid arthritis, ankylosing spondylitis)
• Fully human IgG1 anti-IL17A monoclonal antibody
• Standard dosing (subcutaneous injection): 300mg by injection
• MoA: selectively binds and neutralizes IL-17A
• Launched: March 2015
1. Cosentyx Product Monograph 2015
![Page 29: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/29.jpg)
IXEKIZUMAB
• Indicated for adult moderate to severe PsO
• Humanized IgG1 anti-IL17A monoclonal antibody
• MoA: Selectively binds and neutralizes IL-17A
• Launched: August 2016
• Standard dosing (subcutaneous injection):
• Week 0: 160 mg SC (ie, as two 80-mg injections), THEN
• 80 mg SC q2wks at weeks 2, 4, 6, 8, 10, and 12, THEN
• 80 mg SC q4wks
Taltz Product Monograph 2015
![Page 30: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/30.jpg)
BRODALUMAB
• Indicated for moderate to severe PsO
• Fully human IgG2 anti-IL17Ra monoclonal antibody
• MoA: Inhibits activity of IL-17A, -F, -A/F, and –E (IL-25) by blocking receptor
• Launch: ? 2017
• Standard dosing (subcutaneous injection): 210mg
Brodalumab Product Monograph submitted to Health Canada 2016
![Page 31: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/31.jpg)
BRODALUMABIn the partnership with
AstraZeneca, LEO Pharma acquires the exclusive
licence to Brodalumab in Europe.
![Page 32: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/32.jpg)
IL-23 INHIBITORS
• Guselkumab (Janssen)
• Tildrakizumab (Merck/Sun Pharma)
• Risankizumab (Boehringer/AbbVie)
![Page 33: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/33.jpg)
MECHANISM OF ACTION: USTEKINUMAB VS. GUSELKUMAB
• Mechanism of Action: Ustekinumab vs. Guselkumab
GuselkumabUstekinumab
A. Blauvelt, et al. EADV 2016. VIE16LAT-0080.
![Page 34: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/34.jpg)
BIOSIMILARS: WHAT ARE THEY?• Copy version of original biologic whose data protection
has expired
• Not a generic
• Not entirely identical
• Highly similar reference product re: physiochemical function characteristics/clinical performance
• Extrapolation of efficacy and safety data to other indications require scientific justification
• Risk management should be include plan for post-licensing surveillance
![Page 35: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/35.jpg)
ABP501: HUMIRA BIOSIMILAR - AMGEN• Data phase 3 program biosimilar Humira vs. Humira
• Primary endpoint: PASI improvement at week 16
• Switch to one another at week 50: same efficacy
• Immunogenicity: binding antibody/neutralizing antibody rates the same
• AE/SAE rates similar
• FDA approval Sept 20th 2016
Biosimilar Humira
PASI 75
74.4 82.7
PASI90
47.1 47.4
PASI 100
16.8 20.0
![Page 36: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/36.jpg)
IMPLICATION OF BIOSIMILARS FOR DERMATOLOGY PRACTICE
• Automatic Substitution
• Dermatology standpoint should not be randomly changed
• Impossible to assess loss of efficacy and adjudicate adverse events (AEs)
• Immunogenicity
• All biologics (complete proteins) subject to this
• Post marketing surveillance essential
• Track potential AEs & lack of efficacy
![Page 37: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/37.jpg)
APREMILAST (CELGENE)
• Small-molecule PDE4 inhibitor
• For use in adults with active moderate to severe psoriasis and psoriatic arthritis
• Other uses being investigated:
• Rheumatoid arthritis, ankylosing spondylitis & Behcet’s disease
1. Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis (POSTURE). Clinical Trial. N.p.: Celgene, 2015. NCT01583374.Clinicaltrials.gov. Web. 23 Sept. 2015.
![Page 38: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/38.jpg)
• A multicentre, randomised, double-blind (sponsor-unblinded),placebo-controlled, repeat dose study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active plaque-type psoriasis.
• Status: recruiting
MoA:
GSK2982772 is a first-in-
class, highly selective,
receptor-interacting protein
1 kinase
(RIP1) inhibitor being
developed for the treatment
of inflammatory disease
conditions.
GSK2982772 (GSK) – Oral Medication
"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis." Home. N.p., n.d. Web. 02 Nov. 2016.
![Page 39: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/39.jpg)
ENSTILAR (LEOPHARMA)
• Calcipotriol and betamethasone dipropionate aerosol foam
• Applied to the affected area once daily for 4 weeks Enhanced drug delivery and penetration vs Dovobet® ointment
• Superior efficacy compared to calcipotriol and betamethasone dipropionatealone & and calcipotriol + betamethasone dipropionate combination products (Dovobet gel and ointment)
• Fast and effective itch relief
• Safety and tolerability consistent with other fixed combination products. No clinically relevant impact on HPA axis and calcium homeostasis.
Enstilar Product Monograph, 08 Sep 2016, LEO Pharma Inc 1. Hollesen Basse, et al. J Invest Dermatol 2014;134:abst 192; 2. Queille-Roussel et al. Poster #915; AAD 2015, San Francisco, CA, USA; 3. Lebwohl et al. J Clin Aesthet Dermatol. 2016 Feb; 9(2): 34–41. 4. Koo et al. J Dermatol Treat 2015;1-8; 5. Queille-Roussel et al. Clin Drug Investig. 2015;35:239–245; 6. Paul et al. JEADV 2016 Aug 17; 7. Leonardi et al. J Drugs Dermatol 2015;14:1468–1477; 8. Taraska V, et al. J Cutan Med Surg. 2016;20(1):44-51.
![Page 40: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/40.jpg)
GSK2894512 CREAM (GSK)
• A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
• Study status: recruiting
MoA
GSK2894512 inhibits
leukotriene B4, tumor necrosis factor
alpha (TNF-), and T helper type 17 cells;
inhibits
molecules involved in the adhesion and
recruitment of cells involved in the
pathogenesis
of psoriasis; and activates the aryl
hydrocarbon receptor (AhR) and nuclear
factorerythroid
2-related factor-2 (Nrf2) anti-
inflammatory pathways.
"A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis." Home. Web. 02 Nov. 2016.
![Page 41: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/41.jpg)
ACNE
![Page 42: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/42.jpg)
MSc, Yuka Asai MD, Akerke Baibergenova MD PhD, Maha Dutil MD MEd, Shannon Humphrey BSc MD, Peter Hull MMed PhD, Charles Lynde BSc MD, Yves Poulin MD, Neil H. Shear BASc(Hons) MD, Jerry Tan BSc MD⇑, and John Toole BSc MD. "Yuka Asai." Management of Acne: Canadian Clinical Practice Guideline. N.p., 02 Feb. 2016. Web. 31 Oct. 2016.
![Page 43: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/43.jpg)
ACNE
• Have a large selection of topicals:
• Retinoids
• Benzoyl Peroxides
• Combinations
• Dapsone
… and now…
![Page 44: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/44.jpg)
ADAPALENE AND BENZOYL PEROXIDE TOPICAL GEL, 0.3%/2.5% W/W(TACTUPUMP FORTE GALDERMA)
TactuPump Forte demonstrated significant reductions in inflammatory and non-inflammatory
lesions in severe acne
Tactupump, product monograph, Galderma. 2016.
![Page 45: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/45.jpg)
DRM01- TOPICAL SEBUM INHIBITOR (DERMIRA)
![Page 46: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/46.jpg)
XEN801 TOPICAL GEL (XENON)
A Safety, Tolerability, Efficacy and Exposure Study of XEN801
Topical Gel
• Study Design:
• A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
• Duration: 12 weeks
• Status: Recruiting
MoA: XEN801 is apotent and selective stearoyl-CoA desaturase-1 (SCD1) inhibitor.
![Page 47: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/47.jpg)
CD5789 (GALDERMA)
• A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris
• Status: Recruiting
MoA (retinoid):
In vitro gene transactivation
studies show a very high
selectivity for
RAR over RAR and
RAR.
"Double-Blind Efficacy and Safety of CD5789 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris." Home. N.p., n.d. Web. 02 Nov. 2016.
![Page 48: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/48.jpg)
HORMONAL TREATMENT – BACK IN VOGUE?
• hormonal therapy offers an important treatment option for women with specific acne features
• Strongly consider a patient if: Has a condition associated with hyperandrogenism, has inflammatory acne involving the face and neck, has acne that flares up premenstrually
• Hormonal combination of: 2 mg cyproterone acetate and 0.035 mg ethinyl estradiol tablets (CLEO-35)
• Indicated for women with severe acne
CLEO-35 product monograph, Aspri Pharma, 2016.
![Page 49: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/49.jpg)
ROSACEA
![Page 50: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/50.jpg)
ROSIVIER (GALDERMA)
• Ivermectin 1% cream, supplied in a 60g tube
• Dual action: anti-inflammatory & anti-parasitic
• Vehicle technology based on Cetaphil
• Indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults greater than 18 year of age
• 1x nightly application
• Better tolerated than azelic acid 15% and metronidazole 0.75%
Rosivier, Galderma, product monograph
![Page 51: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/51.jpg)
VITILIGO
• Increased interest by a number of companies
• Currently there is an open-label pilot study exploring the use of Abatacept for the treatment of vitiligo
• MoA: a selective costimulation modulator, inhibits T cell activation and binds to CD80 and CD86 ?? MoA in Vitiligo
• Currently indicated for: rheumatoid arthritis
• (Bristol Meyers Squibb product) Orencia –subcutaneous injection
"Open-label Pilot Study of Abatacept for the Treatment of Vitiligo." Home. N.p., n.d. Web. 02 Nov. 2016.
![Page 52: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/52.jpg)
HIDRADENITIS SUPPURATIVA
… and biologics
![Page 53: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/53.jpg)
RE SEARCH – APPLIED TO HIDRADENITIS SUPPURATIVA
OLD Paradigms NEW Paradigms
OLD CONCEPTS
• Sweat gland disease
• Infection
• Acne spectrum
NEW CONCEPTS
•Follicular cysts = γ secretase
•Inflammasome activation = auto-
inflammation, IL1
•IL17>TNFα (aberrant psoriasis)
OLD TREATMENTS
• Isotretinoin
• Antibiotics
NEW TREATMENTS
•Infliximab (2001), adalimumab
•Anakinra, canakinumab
•Ustekinumab
•Secukinumab, ixekizumab
•(CJM112 – NOVARTIS)
•Tofacitinib, baracitinib
‘NEW’ OLD TREATMENTS
•Methotrexate
•Cyclosporine, prednisonecourtesy of Dr. Jan Dutz
![Page 54: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/54.jpg)
ALOPECIA AREATA
![Page 55: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/55.jpg)
TOFACTINIB
• MoA: JAK Inhibitor
• Tofactinib for the Treatment of Alopecia Areata & Variants
• 2 center, open-label, single arm trial using Tofactinib (5mg) was given 2x daily for 3 months
• N = 66
• 32% of patients experienced 50% or greater improvement in SALT score
• 64% of patients responded to treatment
Crispin, Milène Kennedy, Justin M. Ko, Brittany G. Craiglow, Shufeng Li, Gautam Shankar, Jennifer R. Urban, James C. Chen, Jane E. Cerise, Ali Jabbari, Mårten C.g.Winge, M. Peter Marinkovich, Angela M. Christiano, Anthony E. Oro, and Brett A. King. "Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata." JCI Insight 1.15 (2016): n. pag. Web.
![Page 56: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/56.jpg)
BARICITINIB (ELI LILLY/INCYTE)
• MoA: JAK 1 & 2 inhibitor
• Being developed orally & topically
• Exciting initial results
"Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib." Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.. 02 Nov. 2016.
![Page 57: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/57.jpg)
TOPICAL INCB018424 (INCYTE)
• Status: active, not recruiting
• Study design:
• An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied
MoA: JAK 1 & 2 Inhibitor
![Page 58: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/58.jpg)
ALOPECIA AREATA
A Study of Secukinumab for the Treatment of Alopecia Areata
• Identifier: NCT02599129
• Status: recruiting
• 300 mg subcutaneous injections of Secukinumab vs. placebo
• MoA: IL-17 inhibitor
"A Study of Secukinumab for the Treatment of Alopecia Areata." Home. Web. 02 Nov. 2016.
![Page 59: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/59.jpg)
ALOPECIA AREATA
A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
• Identifier: NCT02684097
• Phase 2
• Status: recruiting
• Randomized study 2:1 Tralokinumab to placebo
• MoA: IL-13 Inhibitor
"A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata." Home. N.p., n.d. Web. 02 Nov. 2016.
![Page 60: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/60.jpg)
ANDROGENIC ALOPECIA & OTHER ALOPECIAS?REVITA (DS LABORATORIES)
• Revita (contains no sodium laureth sulfate, sodium lauryl sulfate that may irritate scalp tissue)
• it deploys natural cleansers; ingredients to increase scalp health
• It is recommended that in conjunction with a topical formulations allows users to address thinning with minimal cost and without any pain or intrusive procedures.
Laboratories, DS. "Revita Shampoo." Revita Shampoo. Web. 02 Nov. 2016.
![Page 61: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/61.jpg)
CHRONIC SPONTANEOUS URTICARIA
![Page 62: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/62.jpg)
TREATMENTS: OMALIZUMAB
• Humanized monoclonal IgG anibody against IgE
• Low immunogenicity
1. Boushey H Jr. J Allergy Clin Immunol 2001;108:S77–83;2. Adapted with permission from Boushey H Jr. J Allergy Clin Immunol 2001;108:S77–83.
![Page 63: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/63.jpg)
BILASTINE
• MoA: high affinity for H1 receptor (antihistamine)
• Bilastine is indicated for the relief of the symptoms associated with chronic spontaneous urticaria (CSU) in patients 18 years of age and older.
• Standard dosing: oral tablet 20mg
• Launch: December 2016
PrBLEXTEN™ Product Monograph
![Page 64: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/64.jpg)
BILASTINE
• Good cardiac safety profile
• H1- receptor occupancy in CNS equal to placebo
• It does not affect functional performance
• It does not affect the ability to drive even at double dose
• It does not potentiate alcohol and/or lorazepam effects
• Significantly better in terms of somnolence than cetirizine
![Page 65: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/65.jpg)
RUPATADINE
• Released by PediaPharm in Canada in July 2016
• Rupatadine is a new second-generation antihistamine and platelet-activating factor (PAF) antagonist
• currently available in 62 countries around the world
• high potency, good efficacy and excellent safety profile of the product have been demonstrated under an extensive clinical development program.
• Rupatadine (Tablet 10mg and Oral Solution 1mg/mL) is indicated for the treatment of the symptoms associated with Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PAR) and Chronic Spontaneous Urticaria (CSU) in patients > 2 years of age
"Pediapharm Receives Health Canada Approval for Rupatadine." Marketwire. N.p., n.d. Web. 02 Nov. 2016.
![Page 66: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/66.jpg)
ONYCHOMYCOSIS
• Oral (adult)
• Terbinafine: 250mg daily for 6-12 weeks
• Itraconazole: 200mg daily for 6-12 weeks
• Fluconazole: 200mg weekly for 9 months
• Topical
• Efinaconazole (Jublia) once daily for 4-8 weeks
• Preventative: ciclopriox olamine (Penlac) –poor success
![Page 67: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/67.jpg)
MOB015B-IV (MOBERG)
Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
• Started recruiting: September 2016
MOB015B is a moderately
viscous solution containing 10%
terbinafine hydrochloride in a
plastic tube with a silicon tip to
facilitate application to the nail.
MoA: inhibits the biosynthesis of
an integral component of fungal cell membranes
"A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)." Home. Web. 02 Nov. 2016.
![Page 68: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/68.jpg)
HSV-1 & HSV-2 SITAVIG (CIPHER)
• Indicated for: recurrent herpes labialis
• Acyclovir 50mg – Sitavig by CipherMuco-adhesive buccal tablet
• MoA: binds to viral DNA polymerase, terminates the DNA chain
• A single dose of Sitavig reduced the viral load in the saliva 5-fold at the site of viral replication (P=.583), possibly reducing the amount of virus available to return into latency.
Sitavig, product monograph, Cipher. 2016
![Page 69: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/69.jpg)
ACTINIC KERATOSIS
![Page 70: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/70.jpg)
ACTIKERALL (CIPHER)
• Topical antineoplastic agent, fluorouracil and salicylic acid, solution (0.5%/10%)
• indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients.
MoA: • Inhibits thymidylate
synthase• Disrupts DNA &
RNA synthesis
Actikerall, product monograph, Cipher. 2016.
![Page 71: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/71.jpg)
PEDIATRICS
• Indicated in: infantile haemangioma
• Hemangiol (Pierre Fabre) – Propranolol hydrochloride, oral solution
• MoA: Beta blocker
• Approval: October 2016
Hemangiol, product monograph, Pierre Fabre. 2016
![Page 72: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/72.jpg)
FILLERSRevanesse (Prollenium Medical Technologies)
• Cross-linked hyaluronic acid
• Canadian company (based in Aurora, Ontario)
• Revanesse dermal fillers have been proven to be safe and effective
• Contains no animal products
• biocompatible and biodegradable
• lower viscosity gel best used to fill superficial imperfections
• Indicated for: fine lines, forehead wrinkles– crow’s feet, perioral lines, labellarlines
• Duration (up to 9 months)
• Available with Lidocaine
"Physician, Revanesse." Revanesse.. Web. 02 Nov. 2016.
![Page 73: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/73.jpg)
MoA: As a bile acid, deoxycholic acid emulsifies fat in the gut. Synthetically derived deoxycholic acid, when injected, stimulates a targeted breakdown of adipose cells by
disrupting the cell membrane and causing adipocytolysis.
DOUBLE CHIN - BELKYRA (ALLERGAN)
Belkyra, product monograph, Allergan. 2016.
![Page 74: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/74.jpg)
KEY TAKEAWAYS - TRENDS
• Increased understanding of immunology and potential targets for many of our diseases that we have poor treatments
• Better treatments for AD, vitiligo, alopecia areata
• PASI 90 & 100 for psoriasis
• Guidelines
• Cost containment? Biosimilars
![Page 75: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/75.jpg)
“We are on the cusp of revolutionary new
products that will change how we treat
dermatologic diseases much like the biologics
brought to our treatment of psoriasis.”
attributed to great philosopher also a
dermatologist
~ CW Lynde
Summary
![Page 76: DERMATOLOGICAL · treatments for mild-to-moderate atopic dermatitis (AD) MoA: PDE4 inhibitor Identifier: NCT01301508 "Efficacy and Safety of AN2898 and AN2728 Topical Ointments to](https://reader034.vdocument.in/reader034/viewer/2022042312/5edb3313e2cb8b542667eb7b/html5/thumbnails/76.jpg)
THANK-YOU
• A special thank-you to Ceilidh Welch